StockData
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. (XENE) stock

XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.78−0.48 (-1.22%)

Close on Nov 17, 2026Market cap $3.76BP/E –Yield –

Xenon Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Xenon Pharmaceuticals's total debt was $15.68M at Mar 31, 2020. For fiscal 2019 it was $15.54M, up 3.5% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2019Dec 31, 2019$15.54M+3.5%
FY2018Dec 31, 2018$15.01M+120.7%
FY2017Dec 31, 2017$6.80M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2020Mar 31, 2020$15.68M+3.5%
Q4 FY2019Dec 31, 2019$15.54M+3.5%
Q3 FY2019Sep 30, 2019$15.40M+3.5%
Q2 FY2019Jun 30, 2019$15.27M+30.3%
Q1 FY2019Mar 31, 2019$15.14M+120.2%
Q4 FY2018Dec 31, 2018$15.01M+120.7%
Q3 FY2018Sep 30, 2018$14.89M–
Q2 FY2018Jun 30, 2018$11.72M–
Q1 FY2018Mar 31, 2018$6.88M–
Q4 FY2017Dec 31, 2017$6.80M–

More Xenon Pharmaceuticals figures

See a number that looks wrong?